Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM01183 (Lurbinectedin) in Metastatic/Unresectable Sarcoma
NCT02448537Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2015
- Primary completion
- Feb 2017
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in soft tissue sarcoma (STS), sponsored by Massachusetts General Hospital. Started Aug 2015; status: completed.
02
Drugs
lurbinectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02448537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02448537.